
Experts say proposed pharmaceutical tariffs could raise drug prices, impacting patient access and health care budgets.

Experts say proposed pharmaceutical tariffs could raise drug prices, impacting patient access and health care budgets.

One-third of F32 grant recipients secure follow-up NIH K awards, fueling new biomedical discoveries and career growth.

The Colorectal Cancer Alliance expands its $100 million Project Cure CRC with 3 new grants driving innovation and improving patient outcomes.

Total neoadjuvant treatment achieved high complete response and organ preservation rates in patients with stage I rectal cancer, according to a new study.

Foster and kinship care children formed stronger bonds with carers, but relationship quality didn’t predict later emotional outcomes, a study finds.

New findings reveal high rates of depression, anxiety, and sleep issues in individuals with psoriatic arthritis and palmoplantar psoriasis.

Higher dietary fiber intake was associated with a reduced risk of moderate to severe diarrhea up to 2 years after diagnosis.

As generative AI tools like ChatGPT, Gemini, and My AI gain popularity, new research highlights their growing role in youth mental health support.

Clinical trials show significant symptom improvement and potential for remission, with a safety profile similar to placebo.

AMCP Nexus connects pharmacy leaders, drives policy change, and empowers members to enhance health care access and improve patient outcomes.

Ketogenic diets were linked to modest reductions in depressive symptoms, especially with ketone monitoring, while anxiety results remain unclear.

Early-onset colorectal cancer (CRC) increases are linked to neuroendocrine tumor reclassification, not true adenocarcinoma growth.

As open enrollment begins November 1, 2025, millions are signing up under enhanced subsidies that are set to expire at the end of this year.

Jo Varshney, PhD, DVM, discusses how artificial intelligence–powered simulations speed drug approvals and reduce clinical trial risk.

Kimberly Westrich, MA, discusses how patient engagement can revolutionize health care decision-making and break down barriers to accessing necessary medicines and care.

Harry Travis, BS Pharm, MBA, explores how artificial intelligence (AI) can revolutionize pharmacy workflows for sustainable productivity gains.

Geni Tunstall, JD, discusses how pharmacy benefit manager reforms, Medicaid changes, and the MAHA initiative may impact managed care pharmacy operations.

Increasing respiratory syncytial virus (RSV) vaccination among older adults could prevent up to 1600 deaths and 20,000 hospitalizations over 5 years.

Brigid Groves, PharmD, MS, discusses the importance of using trustworthy sources so that pharmacists can support communities with accurate information.

Real-world evidence helps pharmaceutical companies and payers communicate more effectively.

Chelsea Renfro, PharmD, discusses the importance of rigorous study designs to establish medication efficacy.

Tildrakizumab maintained a favorable safety profile through 208 weeks in patients with psoriatic arthritis, with no new safety signals reported.

National data show adults struggling to afford energy bills face over twice the odds of depression and anxiety.

More than 50% of patients with psoriasis are eligible for systemic treatment, and nearly 90% would switch to an effective oral therapy with a favorable safety profile.

Ken Cohen, MD, FACP, discusses how new cognitive assessment tools are improving Alzheimer disease diagnosis.

Removing out-of-pocket costs for follow-up colonoscopy led to an immediate and sustained increase in utilization.

Susan Cantrell, CEO of the Academy of Managed Care Pharmacy, shares exclusive insights on key themes that will be discussed at this year's Nexus conference.

Ken Cohen, MD, FACP, discusses how clinicians can support patients after a cognitive screening to identify meaningful next steps.

A study reveals disparities by sex, socioeconomic status, and location for colorectal cancer screenings.

Higher body size and metabolic factors are linked to worse psoriasis and lower biologic treatment success.